Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3635-3640

  Leonard, John P ^a   Jung, Sin Ho ^c   Johnson, Jeffrey ^c   Pitcher, Brandelyn N ^c   Bartlett, Nancy L ^d   Blum, Kristie A ^e   Czuczman, Myron ^b   Giguere, Jeffrey K ^f   Cheson, Bruce D ^g  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f Greenville Community Clinical Oncology Program   (United States)

^g GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPHENHYDRAMINE; HEMOGLOBIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; HEPARIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INFECTION; INTERMEDIATE RISK PATIENT; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; MORTALITY; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPIRIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPARIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; RITUXIMAB; THALIDOMIDE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84944960450     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.9258     Document Type: Article

References (15)

1. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
3. Coiffier B, Osmanov EA, Hong X, et al: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximabsensitive, follicular lymphoma: A randomised phase 3 trial. Lancet Oncol 12:773-784, 2011
4. Cartron G, Zhao-Yang L, Baudard M, et al: Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results: of a phase II study. J Clin Oncol 26:2725-2731, 2008
5. Leonard JP, Schuster SJ, Emmanouilides C, et al: Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113:2714-2723, 2008
6. Pro B, Leber B, Smith M, et al: Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143:355-360, 2008
7. Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552, 2008
8. Ramsay AG, Clear AJ, Kelly G, et al: Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: Implications for the tumor microenvironment and immunotherapy. Blood 114:4713-4720, 2009
9. Witzig TE, Wiernik PH, Moore T, et al: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 27:5404-5409, 2009
10. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36-45, 2008
11. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
12. Jung SH, Kim KM: On the estimation of the binomial probability in multistage clinical trials. Stat Med 23:881-896, 2004
13. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
14. Martin P, Jung S, Johnson J, et al: CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 31, 2013 (suppl 1; abstr 63)
15. Fowler NH, McLaughlin P, Hagemeister FB, et al: Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28, 2010 (suppl 15s, abstr 8036)